DaVita Study Demonstrates Clinical Application Of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter

Sysmex America, Inc. announced that a study titled “Day-to-Day, Week-to-Week, and Day-of-the-Week Variations in Tests of Anemia and Iron Status in Hemodialysis Patients” has identified Sysmex’s Reticulocyte Hemoglobin Equivalent (RET-He) parameter result as key input used by physicians to assist in Anemia treatment decisions in ESRD patients on hemodialysis. David Van Wyck, M.D., Vice President of Clinical Affairs at DaVita Inc.

More: continued here

Filed under: Blood on June 19th, 2009